AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
AbbVie announced positive topline results from the Phase 3 LUNA study, where atogepant met the primary endpoint and all eight ranked secondary endpoints versus placebo for the preventive treatment of menstrual migraine (p<0.0001). Atogepant reduced perimenstrual migraine days by an average of 1.20 days versus 0.40 for placebo across three menstrual cycles — a placebo-adjusted benefit of 0.80 days — in a 468-participant study, with no new safety signals observed.
Key figures
- Drug Name
- atogepant (QULIPTA/AQUIPTA)
- Phase Of Trial
- Phase 3
- P value
- <0.0001
- Trial name
- LUNA (M24-859, NCT06806293)
- Countries approved
- 60
- Participants enrolled
- 468
- Placebo reduction days
- 0.4
- Secondary endpoints met
- 8
- Atogepant reduction days
- 1.2
- Placebo adjusted reduction days
- 0.8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.